{
    "nct_id": "NCT06521554",
    "official_title": "A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)",
    "inclusion_criteria": "1. Age ≥ 18 years\n2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC\n3. Documented HER2 status as follows:\n\n   1. Phase 1a: Documented oncogenic HER2 mutation such as HER2 exon20 insertion mutations or single nucleotide variants or HER2 amplification.\n   2. Phase 1b: Documented oncogenic HER2 mutation.\n4. Identification of lesions as follows:\n\n   1. Phase 1a: Must have evaluable disease (target or nontarget) according to RECIST 1.1.\n   2. Phase 1b: Must have measurable disease, defined as ≥ 1 radiologically measurable target lesion according to RECIST 1.1.\n5. Adequate organ function and bone marrow reserve\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Patient's cancer has known oncogenic driver alteration other than HER2\n2. Known allergy/hypersensitivity to excipients of NVL-330\n3. Major surgery within 4 weeks of the first dose of study drug\n4. Ongoing or recent anticancer therapy\n5. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study",
    "miscellaneous_criteria": ""
}